AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib Ruchika Sharma15 April 2025 3:46 PM ISTBangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg...
Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck Ruchika Sharma11 Dec 2024 5:54 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA...
Cancer drug: AstraZeneca Pharma India bags CSDCO permission to import Lynparza Ruchika Sharma26 Nov 2024 3:54 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the Central Drugs...
Imfinzi, Lynparza combo approved in EU for mismatch repair proficient advanced or recurrent endometrial cancer: AstraZeneca Ruchika Sharma18 Aug 2024 10:00 AM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain...
Lynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca Ruchika Sharma3 July 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU)...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
AstraZeneca's Lynparza plus abiraterone approved in Japan for treatment of BRCA-mutated metastatic castration-resistant prostate cancer Ruchika Sharma26 Aug 2023 11:30 AM ISTCambridge: AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of...
USFDA nod to AstraZeneca, MSD's Lynparza plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma2 Jun 2023 3:30 PM ISTRahway: AstraZeneca and Merck, known as MSD outside of the United States and Canada, has announced that LYNPARZA in combination with abiraterone...
USFDA panel backs restricted use of AstraZeneca Prostrate cancer drug Ruchika Sharma29 April 2023 12:30 PM ISTLynparza belongs to a class of drugs called PARP inhibitors, which include Clovis Oncology's Rubraca and GSK Plc's Zejula.
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 11:30 AM ISTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
Natco Pharma announces submission of ANDA with USFDA for generic version of Olaparib Tablets Ruchika Sharma13 Feb 2023 12:25 PM ISTOlaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer.
AstraZeneca, Merck get Chinese nod for Lynparza to treat ovarian cancer Ruchika Sharma24 Sept 2022 3:24 PM ISTIn China, Lynparza is approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer as well as a 1st-line maintenance...
